Jeffery N Epstein1, Margaret D Weiss. 1. The Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio (Dr Epstein); and The Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (Dr Weiss).
Abstract
OBJECTIVE: To review measures used to assess treatment response in patients with attention-deficit/hyperactivity disorder (ADHD) across the life span. DATA SOURCES: Keyword searches of English-language articles in the PubMed database up to and including the May 4, 2011, index date were performed with the search strings (1) (attention deficit disorder with hyperactivity [MeSH] OR ADHD) AND (outcome assessment [MeSH] OR adaptation of life skills OR executive function [MeSH]) and (2) (attention deficit disorder with hyperactivity [MeSH] OR ADHD) AND (function OR functioning OR quality of life [MeSH]). STUDY SELECTION: Articles found through this search were then selected based on relevance to the topic area; no specific quality criteria were applied. DATA EXTRACTION: Narrative review. RESULTS: The vast majority of studies assessing ADHD treatments have measured treatment response using ADHD symptom measures. Additional domains relevant for assessing treatment response among children and adults with ADHD include functional impairment, quality of life, adaptive life skills, and executive function. Validated rating scales exist for assessing these additional domains, but there has been minimal research evaluating the sensitivity of these instruments for detecting treatment response in pediatric and adult samples. CONCLUSIONS: Assessment of treatment outcomes in ADHD should move beyond symptom assessment to incorporate measures of functioning, quality of life, adaptive skills, and executive function, especially when assessing long-term treatment response. The authors recommend a potential battery and schedule of measures that could be used to more comprehensively assess treatment response in patients with ADHD.
OBJECTIVE: To review measures used to assess treatment response in patients with attention-deficit/hyperactivity disorder (ADHD) across the life span. DATA SOURCES: Keyword searches of English-language articles in the PubMed database up to and including the May 4, 2011, index date were performed with the search strings (1) (attention deficit disorder with hyperactivity [MeSH] OR ADHD) AND (outcome assessment [MeSH] OR adaptation of life skills OR executive function [MeSH]) and (2) (attention deficit disorder with hyperactivity [MeSH] OR ADHD) AND (function OR functioning OR quality of life [MeSH]). STUDY SELECTION: Articles found through this search were then selected based on relevance to the topic area; no specific quality criteria were applied. DATA EXTRACTION: Narrative review. RESULTS: The vast majority of studies assessing ADHD treatments have measured treatment response using ADHD symptom measures. Additional domains relevant for assessing treatment response among children and adults with ADHD include functional impairment, quality of life, adaptive life skills, and executive function. Validated rating scales exist for assessing these additional domains, but there has been minimal research evaluating the sensitivity of these instruments for detecting treatment response in pediatric and adult samples. CONCLUSIONS: Assessment of treatment outcomes in ADHD should move beyond symptom assessment to incorporate measures of functioning, quality of life, adaptive skills, and executive function, especially when assessing long-term treatment response. The authors recommend a potential battery and schedule of measures that could be used to more comprehensively assess treatment response in patients with ADHD.
Authors: Susan Young; Oliver Chadwick; Ellen Heptinstall; Eric Taylor; Edmund J S Sonuga-Barke Journal: Eur Child Adolesc Psychiatry Date: 2005-08 Impact factor: 4.785
Authors: Caroline S Stevenson; Stephanie Whitmont; Laurel Bornholt; David Livesey; Richard J Stevenson Journal: Aust N Z J Psychiatry Date: 2002-10 Impact factor: 5.744
Authors: Betsy Hoza; Alyson C Gerdes; Stephen P Hinshaw; L Eugene Arnold; William E Pelham; Brooke S G Molina; Howard B Abikoff; Jeffery N Epstein; Laurence L Greenhill; Lily Hechtman; Carol Odbert; James M Swanson; Timothy Wigal Journal: J Consult Clin Psychol Date: 2004-06
Authors: Lenard A Adler; Thomas J Spencer; Louise R Levine; Janet L Ramsey; Roy Tamura; Douglas Kelsey; Susan G Ball; Albert J Allen; Joseph Biederman Journal: J Atten Disord Date: 2007-10-29 Impact factor: 3.256
Authors: Tobias Banaschewski; Mats Johnson; Michel Lecendreux; Alessandro Zuddas; Ben Adeyi; Paul Hodgkins; Liza A Squires; David R Coghill Journal: CNS Drugs Date: 2014-12 Impact factor: 5.749
Authors: Peter Nagy; Alexander Häge; David R Coghill; Beatriz Caballero; Ben Adeyi; Colleen S Anderson; Vanja Sikirica; Esther Cardo Journal: Eur Child Adolesc Psychiatry Date: 2015-05-22 Impact factor: 4.785
Authors: Jochen O Mierau; Daphne Kann-Weedage; Pieter J Hoekstra; Lisan Spiegelaar; Danielle E M C Jansen; Karin M Vermeulen; Sijmen A Reijneveld; Barbara J van den Hoofdakker; Erik Buskens; M Elske van den Akker-van Marle; Carmen D Dirksen; Annabeth P Groenman Journal: BMC Pediatr Date: 2020-07-03 Impact factor: 2.125
Authors: Azmi Nasser; Joseph T Hull; Tesfaye Liranso; Gregory D Busse; Zare Melyan; Ann C Childress; Frank A Lopez; Jonathan Rubin Journal: Neuropsychiatr Dis Treat Date: 2021-06-03 Impact factor: 2.570
Authors: Timothy E Wilens; Stephen V Faraone; Paul G Hammerness; Steven R Pliszka; Cassandra L Uchida; Norberto J DeSousa; Floyd R Sallee; Bev Incledon; Jeffrey H Newcorn Journal: J Atten Disord Date: 2021-06-04 Impact factor: 3.256